End-of-day quote
Shanghai S.E.
23:00:00 29/04/2024 BST
|
5-day change
|
1st Jan Change
|
17.43
CNY
|
-.--%
|
|
-3.43%
|
-23.05%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
6,083
|
6,541
|
6,954
|
9,468
|
7,838
|
5,912
|
-
|
-
|
Enterprise Value (EV)
1 |
6,083
|
6,287
|
6,785
|
9,194
|
7,522
|
4,884
|
4,791
|
5,912
|
P/E ratio
|
55.6
x
|
28.8
x
|
28.3
x
|
50.7
x
|
45.3
x
|
28.7
x
|
21.6
x
|
18.9
x
|
Yield
|
1.06%
|
2.41%
|
0.9%
|
1.28%
|
1.77%
|
3.9%
|
3.68%
|
6.94%
|
Capitalization / Revenue
|
9.17
x
|
7.04
x
|
6.33
x
|
7.71
x
|
6.26
x
|
4.24
x
|
3.68
x
|
3.29
x
|
EV / Revenue
|
9.17
x
|
6.77
x
|
6.18
x
|
7.49
x
|
6
x
|
3.5
x
|
2.98
x
|
3.29
x
|
EV / EBITDA
|
38.7
x
|
21.1
x
|
19.7
x
|
35.8
x
|
26.4
x
|
15.1
x
|
11
x
|
11.7
x
|
EV / FCF
|
-
|
-
|
-65,277,182
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.67
x
|
3.9
x
|
3.95
x
|
3.45
x
|
2.93
x
|
2.14
x
|
2
x
|
1.94
x
|
Nbr of stocks (in thousands)
|
321,496
|
315,539
|
314,642
|
346,062
|
346,062
|
339,208
|
-
|
-
|
Reference price
2 |
18.92
|
20.73
|
22.10
|
27.36
|
22.65
|
17.43
|
17.43
|
17.43
|
Announcement Date
|
28/04/20
|
08/03/21
|
28/04/22
|
25/04/23
|
25/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
663.2
|
928.5
|
1,099
|
1,228
|
1,253
|
1,394
|
1,608
|
1,797
|
EBITDA
1 |
157.3
|
297.8
|
343.9
|
256.9
|
285.4
|
324.5
|
436.2
|
504.6
|
EBIT
1 |
106.9
|
246.6
|
284.6
|
183.2
|
193
|
231.6
|
313.4
|
351.5
|
Operating Margin
|
16.12%
|
26.56%
|
25.91%
|
14.92%
|
15.41%
|
16.61%
|
19.49%
|
19.56%
|
Earnings before Tax (EBT)
1 |
117.2
|
260
|
284.2
|
184
|
194.6
|
232.2
|
312.1
|
352.8
|
Net income
1 |
109.2
|
227.7
|
244.1
|
174.1
|
174.5
|
209.6
|
280.1
|
318
|
Net margin
|
16.47%
|
24.53%
|
22.22%
|
14.18%
|
13.93%
|
15.04%
|
17.42%
|
17.7%
|
EPS
2 |
0.3400
|
0.7200
|
0.7800
|
0.5400
|
0.5000
|
0.6080
|
0.8052
|
0.9200
|
Free Cash Flow
|
-
|
-
|
-103.9
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-9.46%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.2000
|
0.5000
|
0.2000
|
0.3500
|
0.4000
|
0.6800
|
0.6415
|
1.210
|
Announcement Date
|
28/04/20
|
08/03/21
|
28/04/22
|
25/04/23
|
25/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
254
|
169
|
274
|
316
|
1,028
|
1,121
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-104
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
6.68%
|
13.9%
|
14.1%
|
8.42%
|
6.31%
|
7.5%
|
9.34%
|
10.2%
|
ROA (Net income/ Total Assets)
|
5.74%
|
11.6%
|
11.6%
|
-
|
-
|
6.16%
|
7.54%
|
8.62%
|
Assets
1 |
1,904
|
1,967
|
2,099
|
-
|
-
|
3,404
|
3,717
|
3,691
|
Book Value Per Share
2 |
5.160
|
5.320
|
5.600
|
7.930
|
7.720
|
8.140
|
8.710
|
9.000
|
Cash Flow per Share
2 |
0.4400
|
0.8100
|
0.6600
|
0.6600
|
0.8000
|
0.8200
|
1.090
|
1.120
|
Capex
1 |
85.1
|
176
|
316
|
356
|
305
|
243
|
230
|
125
|
Capex / Sales
|
12.83%
|
18.98%
|
28.81%
|
29.02%
|
24.31%
|
17.4%
|
14.29%
|
6.94%
|
Announcement Date
|
28/04/20
|
08/03/21
|
28/04/22
|
25/04/23
|
25/04/24
|
-
|
-
|
-
|
Last Close Price
17.43
CNY Average target price
20.24
CNY Spread / Average Target +16.09% Consensus |
1st Jan change
|
Capi.
|
---|
| -23.05% | 817M | | -9.60% | 6.48B | | +24.75% | 3.7B | | -3.20% | 3.1B | | +2.53% | 1.44B | | -15.13% | 1.37B | | -25.63% | 1.24B | | -6.64% | 1.19B | | -10.84% | 1.17B | | -.--% | 1.05B |
Veterinary Drugs
|